Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gastrointestinal Cancers
•
Medical Oncology
•
ASCO 2023
Based on the results of the NORPACT-1 trial presented at ASCO 2023, would you offer upfront surgery or neoadjuvant chemotherapy to early stage pancreatic ductal adenocarcinoma?
Related Questions
What is your approach to liver transplantation candidacy in those with decompensated cirrhosis who have been treated for a solid-organ malignancy, such as oral SCC?
How would you manage a borderline resectable pancreatic cancer s/p induction chemo + chemo-RT who was unable to go to surgery?
Would you ever consider treatment without tissue diagnosis for a gastrointestinal neuroendocrine metastatic tumor based on a positive dotatate scan alone?
What factors would make you choose IPI3/NIVO1 frontline for advanced unresectable and metastatic HCC based on CheckMate 9DW?
Is there a standard of care for management of localized DNA mismatch repair deficient esophagus cancer?
For metastatic cholangiocarcinoma that has progressed on first line chemotherapy and immunotherapy, that is HER2 3+, which HER2 regimen is preferred, TDxD, Zanidatamab or tucatinib/trastuzumab?
What is your institutional practice for neoadjuvant therapy prior to transplanting cholangiocarcinoma?
Do you regularly incorporate oral cryotherapy in your practice for patients receiving oxaliplatin to decrease the risk of thermal hyperalgesia?
Which patients, if any, treated according to PROSPECT for an early stage rectal cancer, would you offer surveillance if they achieved cCR after neoadjuvant chemotherapy?
What are your top takeaways in GI Cancers from ESMO 2024?
